Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.10.5735

Prognostic Role of C-reactive Protein in Gastric Cancer: A Meta-analysis  

Yu, Qing (Department of Oncological Surgery, the First Affiliated Hospital, Zhejiang University)
Yu, Xiong-Fei (Department of Oncological Surgery, the First Affiliated Hospital, Zhejiang University)
Zhang, Shou-De (Sir Run Run Shaw Hospital, Zhejiang University)
Wang, Hao-Hao (Department of Oncological Surgery, the First Affiliated Hospital, Zhejiang University)
Wang, Hai-Yong (Department of Oncological Surgery, the First Affiliated Hospital, Zhejiang University)
Teng, Li-Song (Department of Oncological Surgery, the First Affiliated Hospital, Zhejiang University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.10, 2013 , pp. 5735-5740 More about this Journal
Abstract
Background: A number of studies have investigated the association between increased pretreatment serum C-reactive protein (CRP) levels and the prognosis of gastric cancer. However, due to the inconsistent results, whether the serum CRP level can be a prognostic factor in primary gastric cancer remains controversial. Methods: We searched Medline, PubMed, Embase and the Cochrane Central Register of Controlled Trials for relevant high-quality reports. A meta-analysis was carried out using the included studies to assess the association between pretreatment serum CRP level and overall survival (OS) in patients with gastric cancer. Correlation analyses were conducted to evaluate the relationship between serum CRP and tumor characteristics such as tumor node metastasis (TNM) stage and recurrence. Results: Twelve reports involving 2,597 patients with gastric cancer were included. Primary meta-analysis indicated a significant association between elevated CRP level and poor OS (HR 1.77, 95% CI 1.56-2.00). Subgroup analyses showed no single factor could alter the primary results when we divided the included studies by "number of patients", "max follow-up period", "TNM stage", "treatment" and "cut-off value". Correlation analyses showed that serum CRP level was significantly related to TNM stage (OR 2.96, 95% CI 2.22-3.93) and tumor recurrence (OR 1.81, 95% CI 1.21-2.71). Conclusions: We demonstrated that increased pretreatment serum CRP level (${\geq}10mg/L$) was significantly associated with poor prognosis in gastric cancer patients, either in early or advanced stages.
Keywords
C-reactive protein; gastric carcinoma; prognosis; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ulich TR, Del CJ, Keys M, Granger GA, Ni RX (1987). Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol, 139, 3406-15.
2 Wang DS, Ren C, Qiu MZ, et al (2012). Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage iii gastric cancer. Tumour Biol, 33, 749-56.   DOI   ScienceOn
3 Wells GA, Shea B, O'Connell D, et al (2008). The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm, Accessed 1 January 2008,
4 Woo Y, Hyung WJ, Obama K, et al (2012). Elevated high-sensitivity c-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol, 105, 405-9.   DOI   ScienceOn
5 Zheng ZX, Zheng RS, Chen WQ (2013). An analysis of incidence and mortality of stomach cancer in china, 2009. China Cancer, 327-32.
6 Aizawa M, Gotohda N, Takahashi S, Konishi M, Kinoshita T (2011). Predictive value of baseline neutrophil/lymphocyte ratio for t4 disease in wall-penetrating gastric cancer. World J Surg, 35, 2717-22.   DOI
7 Balkwill F, Mantovani A (2001). Inflammation and cancer: back to virchow? Lancet, 357, 539-45.   DOI   ScienceOn
8 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.   DOI   ScienceOn
9 Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78.   DOI   ScienceOn
10 Caruso R, Pallone F, Monteleone G (2007). Emerging role of il-23/il-17 axis in h pylori-associated pathology. World J Gastroenterol, 13, 5547-51.   DOI
11 Catalano V, Labianca R, Beretta GD, et al (2009). Gastric cancer. Crit Rev Oncol Hematol, 71, 127-64.   DOI   ScienceOn
12 Chang CC, Sun CF, Pai HJ, et al (2010). Preoperative serum c-reactive protein and gastric cancer; Clinical-pathological correlation and prognostic significance. Chang Gung Med J, 33, 301-12.
13 Chen W, Zheng R, Zhang S, et al (2013). Report of incidence and mortality in china cancer registries, 2009. Chin J Cancer Res, 25, 10-21.
14 Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 52, 6735-40.
15 Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.   DOI   ScienceOn
16 Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
17 Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006). Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer, 94, 637-41.
18 Crumley AB, Stuart RC, McKernan M, McMillan DC (2010). Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg, 34, 2393-8.   DOI
19 Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.   DOI   ScienceOn
20 Forman D (2001). Gastric cancer and helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut, B, 347-53.
21 Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003). Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer, 89, 1028-30.   DOI   ScienceOn
22 Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med, 340, 448-54.   DOI   ScienceOn
23 Gencer D, Kastle-Larralde N, Pilz LR, et al (2009). Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie, 32, 380-6.
24 Hurlimann J, Thorbecke GJ, Hochwald GM (1966). The liver as the site of c-reactive protein formation. J Exp Med, 123, 365-78.   DOI   ScienceOn
25 Hashimoto K, Takashima A, Nagashima K, et al (2010). Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol, 136, 1059-64.   DOI
26 Heikkila K, Ebrahim S, Lawlor DA (2007). A systematic review of the association between circulating concentrations of c reactive protein and cancer. J Epidemiol Community Health, 61, 824-33.   DOI   ScienceOn
27 Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
28 Hwang JE, Kim HN, Kim DE, et al (2011). Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer, 11, 489.   DOI
29 Iwasa S, Nakajima TE, Nakamura K, et al (2011). Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study. Int J Clin Oncol, 16, 57-62.   DOI
30 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
31 Jeong JH, Lim SM, Yun JY, et al (2012). Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology, 83, 292-9.   DOI   ScienceOn
32 Kao SC, Pavlakis N, Harvie R, et al (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res, 16, 5805-13.   DOI
33 Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature, 454, 436-44.   DOI   ScienceOn
34 Karakiewicz PI, Hutterer GC, Trinh QD, et al (2007). C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a european study of 313 patients. Cancer, 110, 1241-7.   DOI   ScienceOn
35 Kwon HC, Kim SH, Oh SY, et al (2012). Clinicopathologic significance of expression of nuclear factor-kappab rela and its target gene products in gastric cancer patients. World J Gastroenterol, 18, 4744-50.   DOI   ScienceOn
36 Macdonald JS, Smalley SR, Benedetti J, et al (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345, 725-30.   DOI   ScienceOn
37 Mohri Y, Tanaka K, Ohi M, et al (2010). Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg, 34, 285-90.   DOI
38 Nozoe T, Iguchi T, Adachi E, Matsukuma A, Ezaki T (2011). Preoperative elevation of serum c-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today, 41, 510-3.   DOI
39 Parsonnet J, Friedman GD, Vandersteen DP, et al (1991). Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med, 325, 1127-31.   DOI   ScienceOn
40 Pine JK, Fusai KG, Young R, et al (2009). Serum c-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol, 35, 605-10.   DOI   ScienceOn
41 Talmadge J E, Fidler I J (2010). Aacr centennial series: the biology of cancer metastasis: historical perspective. Cancer Res, 70, 5649-69.   DOI
42 Proctor MJ, Morrison DS, Talwar D, et al (2011). An inflammation-based prognostic score (mgps) predicts cancer survival independent of tumour site: a glasgow inflammation outcome study. Br J Cancer, 104, 726-34.   DOI   ScienceOn
43 Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with s-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20.   DOI   ScienceOn
44 Shimura T, Kitagawa M, Yamada T, et al (2012). C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res, 32, 491-6.
45 Tillett W S, Francis T (1930). Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med, 52, 561-71.   DOI
46 Ulich TR, Del CJ, Guo K, Souza L (1989). The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin-1, and granulocyte-colony stimulating factor on bone marrow and circulation. Am J Pathol, 134, 149-59.
47 Bonner JA, Harari PM, Giralt J, et al (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 11, 21-8.   DOI   ScienceOn
48 Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.   DOI
49 Fujitani K, Yamada M, Hirao M, Kurokawa Y, Tsujinaka T (2011). Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction. Gastric Cancer, 14, 353-9.   DOI   ScienceOn